Safety and efficacy of intra-procedural landiolol, a very short acting beta-1 adrenergic receptor blocker, in primary percutaneous coronary intervention for acute myocardial infarction

Safety and efficacy of intra-procedural landiolol, a very short acting beta-1 adrenergic receptor blocker, in primary percutaneous coronary intervention for acute myocardial infarction - Safety and efficacy of landiolol in primary percutaneous coronary intervention for acute myocardial infarction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021668

Enrollment

Registered

2016-03-29

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Landiolol (3mcrg/kg/min) is started while performing primary percutaneous coronary intervention for acute myocardial infarction. It continues 6-24 hours after the admission.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute myocardial infarction who treated by primary percutaneous coronary intervention

Exclusion criteria

Exclusion criteria: HR<50bpm Killip>2 History of myocardial infarction 2or3 AV block B blocker before admission History of asthma

Design outcomes

Primary

Measure	Time frame
Primary efficacy endpoint was reperfusion status after the repercussion therapy, assessed by ST resolution, myocardial blush grade, TIMI flow, and creatine kinase and safety endpoint was adverse cardiac events during admission and within 12 months after the discharge of those patients.	—

Countries

Japan

Contacts

Public ContactMasayoshi Kiyokuni

Yokohama City University Graduate School of Medicine Cardiorenal science

masakiyo@yokohama-cu.ac.jp045-832-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026